Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - AVEO PHARMACEUTICALS, INC. | aveo-ex322_12.htm |
| EX-32.1 - EX-32.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex321_8.htm |
| EX-31.2 - EX-31.2 - AVEO PHARMACEUTICALS, INC. | aveo-ex312_14.htm |
| EX-31.1 - EX-31.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex311_15.htm |
| EX-21.1 - EX-21.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex211_10.htm |
| EX-10.28 - EX-10.28 - AVEO PHARMACEUTICALS, INC. | aveo-ex1028_1053.htm |
| EX-10.27 - EX-10.27 - AVEO PHARMACEUTICALS, INC. | aveo-ex1027_964.htm |
| EX-3.1 - EX-3.1 - AVEO PHARMACEUTICALS, INC. | aveo-ex31_621.htm |
| 10-K - 10-K - AVEO PHARMACEUTICALS, INC. | aveo-10k_20201231.htm |
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statement (Form S-8 Nos. 333-221838, 333-189565, 333-175390, 333-165530 and 333-250276) of AVEO Pharmaceuticals, Inc., and |
|
|
(2) |
Registration Statement (Form S-3 No. 333-212051, No. 333-221837, and No. 333-249982) of AVEO Pharmaceuticals, Inc.; |
of our reports dated March 16, 2021, with respect to the consolidated financial statements of AVEO Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Aveo Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
March 16, 2021